Member Directory - Viral Hepatitis Working Group

Chair: David Thomas

Objectives:

  • Promote development of long-acting approaches to the treatment and/or prevention of hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. With HCV infection, the ultimate goal is a ‘test and cure’ approach to elimination.  With HBV infection, long-acting formulations to simplify treatment and prevention.
  • Bring clinical, public health, and regulatory expertise to solve this pharmacological challenge by identifying the optimal drug targets and encouraging their development in partnership with Pharma.  
  • Prioritize existing compounds with the pharmacologic and chemical properties that support long-acting formulation.

Interested in joining?

Please submit your request and your CV to Ana Cervantes. Acceptance requires a written nomination from a Hepatitis Working Group member and majority approval.

David Thomas is Director of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine at the Johns Hopkins School of Medicine.

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Dr. Bollinger is Founding Director of the Center for Clinical Global Health Education (CCGHE) and Professor of Infectious Diseases at the Johns Hopkins University (JHU) School of Medicine.

Conflict of Interest: I am a member of a Data Monitoring Committee for Merck & Co.

Daniel E Cohen, MD, is a Group Medical Director in Clinical Development at AbbVie.

Conflict of Interest: Dr. Cohen is an employee and stockholder of AbbVie.

Dr. Feld attended medical school at the University of Toronto and then completed residency programs in Internal Medicine and Gastroenterology.

Conflicts of Interest: Dr. Jordan Feld received Personal fees for scientific consulting from: Abbott, Abbvie, Gilead, Enanta, Roche. Dr. Feld reports receiving grants for research from Abbvie, Gilead, Janssen, Wako/Fujifilm 

Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP).

Conflict of Interest: Dr. Flexner has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Algernon Pharmaceuticals; Gilead; Merck; Mylan Pharmaceuticals; ViiV Healthcare. 

Lobna Gaayeb manages the Long-Acting Technologies project at the Medicines Patent Pool. She has experience in coordinating international networks and scientific projects.

Conflict of Interest: 

Leah Johnson, PhD, is a Senior Research Chemist in the Center for Engineered Systems at RTI International.

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Mila Maistat works as Policy and Advocacy Manager with the Medicines Patent Pool (MPP). She has almost 20 years of experience of working in public health, in particular, viral hepatitis and HIV policy, advocacy and access to medicines. 

Conflict of Interest: 

Craig McClure leads the Viral Hepatitis Program at the Clinton Health Access Initiative (CHAI).

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Leonard A Sowah, MBChB, MPH, is a medical officer at the Division of AIDS in the Complications and Coinfections Research Branch.

Disclosures: I have no disclosures to declare.

Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases Johns Hopkins Bayview Medical Center.

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Dr. Norah Terrault is Professor of Medicine and Chief of Gastroenterology and Liver Diseases at the Keck School of Medicine at University of Southern California.

Conflict of Interest: Dr. Terrault has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Gilead, CCO Hepatitis, Allergan Pharmaceuticals, Dova Pharmaceuticals, Intercept, EXIGO Management Consultants, LLC, Genetech & Roche.